Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.

Hu XW, Qin SM, Li D, Hu LF, Liu CF.

Acta Neurol Scand. 2013 Aug;128(2):73-82. doi: 10.1111/ane.12106. Epub 2013 Feb 21. Review.

PMID:
23432663
2.

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, Livrea P.

Mov Disord. 2005 Jan;20(1):69-72.

PMID:
15390046
3.

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.

Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, Fraddosio A, Iliceto G, Livrea P.

Parkinsonism Relat Disord. 2005 Mar;11(2):131-3. Epub 2004 Dec 20.

PMID:
15734674
4.

Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?

Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P.

Curr Med Chem. 2010;17(3):213-21. Review.

PMID:
20214564
5.

Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P.

Neurol Sci. 2010 Oct;31(5):565-9. doi: 10.1007/s10072-010-0262-0. Epub 2010 May 13.

PMID:
20464572
6.

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.

Yuan RY, Sheu JJ, Yu JM, Hu CJ, Tseng IJ, Ho CS, Yeh CY, Hung YL, Chiang TR.

J Neurol Sci. 2009 Dec 15;287(1-2):64-8. doi: 10.1016/j.jns.2009.09.007. Epub 2009 Sep 27.

PMID:
19786283
7.

Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.

Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, Canesi M, Cristina S, Marchese R, Pacchetti C, Zagaglia R, Logroscino G, Defazio G, Lamberti P, Livrea P.

Mov Disord. 2009 May 15;24(7):1028-33. doi: 10.1002/mds.22511.

PMID:
19353704
8.

Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.

Hassin-Baer S, Cohen O, Vakil E, Sela BA, Nitsan Z, Schwartz R, Chapman J, Tanne D.

Clin Neuropharmacol. 2006 Nov-Dec;29(6):305-11.

PMID:
17095893
9.

Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.

Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro G.

Nutr Neurosci. 2006 Feb-Apr;9(1-2):11-6. Review.

PMID:
16910165
10.

Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.

Ojo OO, Oladipo OO, Ojini FI, Sanya EO, Danesi MA, Okubadejo NU.

West Afr J Med. 2011 Sep-Oct;30(5):319-24.

PMID:
22752818
11.

Serum homocysteine and physical exercise in patients with Parkinson's disease.

Nascimento CM, Stella F, Garlipp CR, Santos RF, Gobbi S, Gobbi LT.

Psychogeriatrics. 2011 Jun;11(2):105-12. doi: 10.1111/j.1479-8301.2011.00356.x.

12.

Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.

Sapkota S, Gee M, Sabino J, Emery D, Camicioli R.

Mov Disord. 2014 Mar;29(3):368-74. doi: 10.1002/mds.25798. Epub 2014 Jan 6.

PMID:
24395213
13.

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

Müller T, Kuhn W.

Mov Disord. 2009 Jul 15;24(9):1339-43. doi: 10.1002/mds.22607.

PMID:
19425084
14.

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.

Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, de Mari M, Livrea P.

Clin Chem Lab Med. 2005;43(10):1107-10.

PMID:
16197306
15.

Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.

Camicioli RM, Bouchard TP, Somerville MJ.

Mov Disord. 2009 Jan 30;24(2):176-82. doi: 10.1002/mds.22227.

PMID:
18951534
16.

Plasma homocysteine levels in pergolide-treated Parkinson disease patients.

Ozkan S, Colak O, Kutlu C, Ertan M, Alatas O.

Clin Neuropharmacol. 2004 Jul-Aug;27(4):163-5.

PMID:
15319701
17.

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

Valkovic P, Benetin J, Blazícek P, Valkovicová L, Gmitterová K, Kukumberg P.

Parkinsonism Relat Disord. 2005 Jun;11(4):253-6. Epub 2005 Apr 20.

PMID:
15878587
18.

Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.

Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA.

Neurology. 2003 Apr 8;60(7):1125-9.

PMID:
12682318
19.

Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.

Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Jarosz M, Gołąb-Janowska M, Koziorowska-Gawron E, Droździk M, Sławek J.

Pharmacogenet Genomics. 2012 Oct;22(10):716-24. doi: 10.1097/FPC.0b013e32835693f7.

PMID:
22890010
20.

Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.

Zoccolella S, Lamberti P, Iliceto G, Dell'Aquila C, Diroma C, Fraddosio A, Lamberti SV, Armenise E, Defazio G, de Mari M, Livrea P.

Clin Chem Lab Med. 2006;44(7):863-6.

PMID:
16776634

Supplemental Content

Support Center